Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The Biden administration surprised the world last night by coming out in favor of waiving patents for coronavirus vaccines — but Europe is divided on the issue.

What they're saying: European Commission President Ursula Von Der Leyen said Brussels would be willing to discuss it; French President Emmanuel Macron said he backed the U.S. position, but a German government spokesman said the proposal would cause "severe complications" for vaccine production.

  • Some European officials also took swipes at the U.S. for coming to the vaccine equity table late, after declining to export any vaccines at all until recently.
  • At least 80 countries, led by India and South Africa, have called for vaccine IP to be waived, while rich countries and pharmaceutical companies had generally opposed the move.

The state of play: This issue is heading to the WTO, and will likely take months to resolve. It would then take at least several months more for facilities in the developing world to start pumping out vaccines.

  • Even then, most of the bottlenecks that are currently slowing global production — shortages of ingredients or vials, for example — will still exist, and the logistics of bringing new facilities on line will be complicated.
  • Still, waiving the patents could allow producers in countries like Bangladesh and South Africa to start producing doses, potentially increasing the supply to developing countries in the medium term.

In other news...

  • The COVAX initiative announced Thursday that it purchased 350 million doses of the Novavax vaccine for delivery beginning in Q3, pending regulatory approval. The U.S. could also begin sharing doses of the American-made vaccine once it's approved.
  • German firm CureVac will soon release trial data for its RNA vaccine, which — unlike Pfizer and Moderna — can be kept at normal refrigerated temperatures. That could make it a genuine game-changer.
  • Canada authorized the Pfizer/BioNTech vaccine for children as young as 12. The U.S. is likely to follow suit as early as next week.

Go deeper: U.S. could fill "vaccine diplomacy" void as other powers struggle

Go deeper

May 6, 2021 - World

Germany opposes Biden's support for waiving vaccine patents

German Chancellor Angela Merkel speaking in Berlin in November 2020. Photo: Maja Hitij/Getty Images

The Biden administration's support for a proposal to waive certain patent protections for coronavirus vaccines would create “severe complications” for vaccine production, a German government spokesperson said Thursday, according to Bloomberg.

Why it matters: The patent waiver proposal, which proponents say will help increase vaccine production and deliver doses to the developing world, is working its way through the World Trade Organization and all 164 member countries will have to consent to the decision, according to Reuters.

Caitlin Owens, author of Vitals
May 6, 2021 - Health

Why waiving vaccine patents might be a bad idea

Illustration: Aïda Amer/Axios

It will take more than waiving patent protections for coronavirus vaccines — which the Biden administration now says it supports — to fix the gaping global divide in access.

Why it matters: Waiving drug companies' intellectual property rights risks setting a bad precedent for future investment in new drugs. And that risk may not be worth it without additional steps to meaningfully increase the availability of shots across the world.

Schools unlikely to require COVID vaccine as teens become eligible

Illustration: Sarah Grillo/Axios

Even if most middle and high schoolers become eligible for the COVID-19 vaccine over the summer, most schools aren't likely to mandate them, at least not this year.

Driving the news: The Food and Drug Administration is expected to authorize the use of the Pfizer COVID-19 vaccine for 12- to 15-year-olds soon.